Severity: Warning
Message: Undefined array key 1
Filename: helpers/my_audit_helper.php
Line Number: 6993
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 6993
Function: _error_handler
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3911
Function: getTopKeywords
File: /var/www/html/application/controllers/Detail.php
Line: 38
Function: pubMedSearch_Global
File: /var/www/html/index.php
Line: 316
Function: require_once
Download full-text PDF |
Source |
---|
Immunotherapy
March 2025
Department of Medical Oncology, Metaxa Cancer Hospital of Piraeus, Piraeus, Greece.
Immunotherapy for gastrointestinal cancers has elicited considerable amount of attention as a viable therapeutic option for several cancer types. Gut microbiome as a whole plays a critical role in shaping immune responses and influencing cancer progression. Recent evidence suggests that (), may influence immunotherapy efficacy by modulating the tumor microenvironment.
View Article and Find Full Text PDFSemin Nephrol
March 2025
Renal Division, Peking University First Hospital, Beijing, People's Republic of China; Kidney Genetics Center, Peking University Institute of Nephrology, Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, People's Republic of China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, People's Republic of China; State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, People's Republic of China. Electronic address:
IgA nephropathy (IgAN), the most prevalent primary glomerulonephritis worldwide, carries a considerable lifetime risk of kidney failure. The etiology of IgAN, however, remains incompletely understood, and effective treatment is lacking. Although the multihit model effectively identifies key steps in IgAN development and, to date, provides the best description of IgAN pathogenesis, it remains under development to fully capture the complexity of immune system dysregulation.
View Article and Find Full Text PDFSemin Nephrol
March 2025
Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL.
IgA nephropathy is a mesangioproliferative glomerular disease with significant morbidity and mortality. Most patients with IgA nephropathy develop kidney failure in their lifetime, reducing their life expectancy by a decade. Since its first description in 1968, it has been established that kidneys of IgA nephropathy patients are injured as "innocent bystanders" by nephritogenic IgA1-containing immune complexes.
View Article and Find Full Text PDFBiosens Bioelectron
March 2025
Key Laboratory of Biology and Genetic Improvement of Oil Crops, Ministry of Agriculture and Rural Affairs; Laboratory of Risk Assessment for Oilseed Products (Wuhan), Ministry of Agriculture and Rural Affairs; Quality Inspection and Test Center for Oilseed Products, Ministry of Agriculture and Rural Affairs; Oil Crops Research Institute, Chinese Academy of Agricultural Sciences, Wuhan, 430062, China; Food Safety Research Institute, HuBei University, Wuhan, China. Electronic address:
Transplant Proc
March 2025
Graduate School of Bengbu Medical University, Bengbu Medical University, Bengbu, Anhui, China; Department of Liver Transplantation, The First Affiliated Hospital of USTC, Division of Life Science and Medicine, University of Science and Technology of China, Hefei, Anhui, China. Electronic address:
Immunotherapy, primarily with immune checkpoint inhibitors, has become pivotal in the treatment of advanced hepatocellular carcinoma (HCC), leading to significant tumor burden reduction. However, its applicability in liver transplantation remains controversial. Due to the potential risks of rejection limiting large-scale clinical trials and the incomplete understanding of underlying mechanisms, whether transplant recipients can benefit from immunotherapy remains uncertain.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!